Privia Health Group, Inc. (PRVA)
NEUTRALFondamental
62
Prix
$21.03
Capitalisation boursière
$2.70B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. The company was founded in 2007 and is headquartered in Arlington, Virginia.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$2.36B
12 derniers mois (au 30/06/2026)
Résultat net
$28M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
-
Capitaux propres totaux
$737M
Passif total
$578M
Ratio de liquidité général
1.62
Couverture des intérêts
-
Dette/EBITDA
0.20
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$19.19
Prix actuel
$21.03
Marge de sécurité
-9.6%
Fourchette de juste valeur
$12.47 - $25.90
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
95.55
ROE
3.1%
Ratio P/B
3.43
P/FCF
-
Marge brute
-
ROIC
4.2%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
4.2%
WACC
8.9%
ROIC − WACC
-4.8 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (13)
- EPS shows upward trend
- EPS CAGR 12.25%
- Debt/Equity ratio
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Revenue Growth 5Y 21.0%
- Analyst Consensus 88% Buy
- Earnings Surprise avg 3.9%
- Earnings Quality (OCF/NI) 4.66
- Share Dilution -2.6%
- Net Margin Trend 1.2% vs 0.8%
- Piotroski F-Score 6/9
Échoué (8)
- Price CAGR -3.98%
- ROIC 4.2%
- P/B Ratio 3.43
- Operating Margin 1.9%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.8%
Indisponible (7)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Parth Mehrotra | CEO & Director | 46 |
| Mr. David Mountcastle CPA, MBA | Executive VP & CFO | 55 |
| Mr. Edward Christopher Fargis Esq. | Executive VP, General Counsel, Chief Legal Officer & Corporate Secretary | 60 |
| Mr. Sarath Degala | Chief Operating Officer | - |
| Mr. Konda Mullapudi | Executive VP & CTO | - |
| Mr. Robert P. Borchert | Senior Vice President of Investor Relations & Corporate Communications | - |
| Ms. Dana Fields CPA | Chief Audit & Compliance Officer | - |
| Ms. Jenny Harding | Chief People Officer | - |
| Mr. Jay Stevens | Senior VP & Chief Growth Officer | - |
| Mr. Eric J. Beyer | Executive Vice President of Medical Groups | - |
Risque d'audit
1
Risque du conseil
2
Risque de rémunération
3
Risque droits des actionnaires
6
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for PRVA, sourced from Markets Gazette.
- 2/26/2026NEUTRALPrivia Health (PRVA) Q4 2025 Earnings Transcript
The financial market is currently awaiting the detailed transcript of Privia Health's (PRVA) Q4 2025 earnings call. While the specific content remains unavailable, investors will be keenly scrutinizing this document for clarity on the company's financial health and future trajectory. Earnings transcripts are vital as they provide direct insights from management discussions, detailing revenues, profits, operating margins, and crucially, future guidance. The current lack of concrete data keeps the stock in a state of anticipation, with market participants looking for signals regarding patient growth, geographical expansion, and cost management strategies. The stock's reaction will heavily depend on the tone and figures revealed once the full transcript is released.
via Markets Gazette